Beyfortus study published in The Lancet Infectious Diseases shows benefit for infants beyond first RSV season First study showing that…
Oslo, Norway, 12th of February 2026 Vistin Pharma ASA (VISTN) today announces the financial results for the fourth quarter and…
Exceeding latest 2025 guidance following a strong performance from both commercial arms of the business in Travel Health and Public…
Männedorf, Switzerland, February 10, 2026 – The Tecan Group (SIX Swiss Exchange: TECN) will hold an Analyst and Media Conference…
Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease Recommendation supported by safety and efficacy…
Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on…
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 17 October 2025 – 6PM CET Fagron’s share buy-back program: Weekly update In the period…
Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation The fund…
Availability of the Q3 2025 Aide mémoire Paris, France – September 24, 2025. Sanofi announced today that its Q3 2025…
COPENHAGEN, Denmark, August 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress…